Savaysa, the anti-clotting drug of Japanese origin, was given approval for retail by the U.S FDA today. It can now be recommended to patients with atrial fibrillation. Savaysa lessens the risk of systemic embolism and strokes.
Atrial fibrillation is one of the most widely known type of irregular heartbeat condition. When a patient is suffering from atrial fibrillation, their heartbeat experiences accelerated and abnormal heartbeat as a result of the malformation of the upper chamber or auricles of the heart. The condition increases blood clotting, and hinders the blood flow from and to other body parts, including the brain itself.
According to Norman Stockbridge, director of the Division of Cardiovascular and Renal Products in the FDA’s Center for Drug Evaluation and Research, Savaysa was able to reduce risk of strokes by preventing blood clot from forming in the heart.
21,000 patients suffering from atrial fibrillation were tested by giving a dose of Savaysa and was then compared to other anti-clotting drug. Based on the outcome of the study, there is less bleeding with Savaysa, but is otherwise just as effective as any other anti-clotting drug.
The effect of Savaysa was also tested on people with pulmonary embolism and vein thrombosis, and the results showed that 3.2% of the people who took the drug had symptomatic venous thromboembolism.
The only side effect of Savaysa so far is bleeding and anemia, which is common when having any other anti-clotting drug too, according to the US Food and Drug Administration. At the moment, the worst side effect of any anti-clotting drug is bleeding and there is no alternative drug found that could combat this.